Sugemalimab
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb) . Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research[1].
Product Specifications
CAS Number
2256084-03-2
UNSPSC
12352203
Target
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sugemalimab.html
Purity
98.3
Solubility
H2O
Smiles
[Sugemalimab]
Molecular Weight
(143.33 kDa)
References & Citations
[1]Dhillon S, et al. Sugemalimab: First Approval. Drugs. 2022 Apr;82 (5) :593-599.|[2]Zhang J, et al. The preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation. Cancer Research, 2020, 80 (16_Supplement) : 3260-3260.
Shipping Conditions
Blue Ice
Storage Conditions
Store at 4°C for 2 years, do not freeze
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC400076 20 µg
CD18 (ITGB2) (NM_000211) Human Over-expression Lysate
Sign In for Pricing
View Details 
